Introduction
============

There has recently been increased interest in identifying non-pharmacologic interventions for improving symptom control during and after cancer care. Symptoms may develop as a result of the cancer or its treatment, with some symptoms persisting long after treatment is complete. Complementary therapies such as acupuncture may be well suited to provide symptomatic relief, alone or in conjunction with other symptom control approaches including pharmaceuticals. According to the National Center for Complementary and Integrative Health (NCCIH), acupuncture falls under the category of mind and body complementary health approaches. A recent review of National Cancer Institute-designated comprehensive cancer centers identified acupuncture and massage (73.3% each) as the most frequently available integrative therapies onsite.[@B1] With increased availability of complementary health approaches such as acupuncture in western medical settings, there is also an increased interest in learning more about the immediate and long term benefits of such interventions on symptom control and quality of life. Insight into the effects of complementary health approaches in a real-world setting may help inform clinical decision making beyond what is already known in the literature through controlled trial settings.

At the MD Anderson Cancer Center, our Integrative Medicine Center offers acupuncture treatments to cancer patients together with conventional care. Patients referred to the Integrative Medicine Center are evaluated by a physician with the goal of developing an integrative oncology treatment plan that may include referral to additional clinical services such as acupuncture, massage, nutrition, physical therapy, and/or health psychology. A part of an effort to document real-world effects, we have previously reported on the effects of an integrative oncology physician consultation on patient self-reported symptoms and quality of life.[@B2] Integrative oncology refers to "a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment.\"[@B3] Our current interest is to expand on current knowledge about the real-world effects of acupuncture, an integrative oncology clinical service, in an oncology care setting.

Acupuncture is an intervention that includes the placement of stainless-steel needles in specific locations throughout the body to help provide relief for one or more symptoms. It has been used as part of medical systems such as traditional Chinese medicine for thousands of years. As an intervention, acupuncture is considered safe with the most common non-serious adverse events including needling pain, hematoma/bleeding, and orthostatic symptoms.[@B4] A number of studies have been completed demonstrating the benefits of acupuncture in helping to provide relief for cancer-related symptoms. In a systematic review of randomized-controlled trials using acupuncture by Garcia et al, the greatest benefits were achieved for relief of symptoms including pain and nausea/vomiting.[@B5] Data recently presented from a SWOG phase III clinical trial revealed benefits of acupuncture for relief of aromatase inhibitor induced join pain and stiffness in post-menopausal women receiving treatment for hormone sensitive breast cancer.[@B6] We have previously reported on our experience with offering acupuncture treatments in an inpatient setting, with clinically significant improvement in symptoms of pain, sleep disturbance, anxiety, nausea, and drowsiness.[@B7] Although numerous clinical trials have demonstrated a benefit of acupuncture in improving patient symptoms and quality of life during and after cancer care, these findings do not necessarily translate into changes observed in a real-world clinical setting.

Although there is evidence of the beneficial effects of acupuncture for symptom control in clinical trial settings, little is known about the effects of acupuncture when implemented alongside conventional cancer care in an outpatient setting. Our current study examined the immediate pre/post treatment and longitudinal/multiple treatment effects of acupuncture on patient self-reported symptoms in an outpatient clinical setting at a comprehensive cancer center.

Methods
=======

Patients were referred to the Integrative Medicine Center from within our institution for evaluation by a physician. Subsequent referral to acupuncture was made based on physician judgement after review of a patient\'s oncology care history and symptom profile. A physician or advanced practice provider order from within our center was required to schedule an initial acupuncture treatment. Acupuncture was available as a fee-for-service, with reimbursement depending on individual insurance plan coverage. Those patients demonstrating financial need had access to acupuncture via available philanthropic funds. As acupuncture treatments were delivered as part of the standard of care within our clinical center; there was no control group.

Prior to each acupuncture treatment, the acupuncturist reviewed the patient\'s medical history, chief complaint/reason for referral, lab-work, and concurrent medications as per safety guidelines established by our program. As part of the standard of care, patients were asked to complete the Edmonton Symptom Assessment Scale (ESAS) on an electronic tablet immediately prior to and after the acupuncture visit. The acupuncturist had access to review the symptom profile prior to the intervention to help in developing a personalized treatment plan. As part of an IRB approved protocol, patient reported outcomes data were analyzed for the period January 1, 2016 to Dec 31, 2016.

Outcome Measures
----------------

Patient symptom burden was assessed using a modified version of the ESAS including 10 core symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, loss of appetite, decreased sense of well-being, shortness of breath, and sleep) and an additional 6 items of spiritual distress, financial distress, numbness/tingling, hot flashes, dry mouth, and memory.[@B8],[@B9] Symptoms were scored on a numeric scale of 0 to 10 (10 = worst possible experience of that symptom). ESAS subscales analyzed included Global Distress (GDS, 0-90, pain, fatigue, nausea, drowsiness, appetite, shortness of breath, anxiety, depression, and well-being), Physical Distress (PHS, 0-60, pain, fatigue, nausea, drowsiness, appetite, and shortness of breath), and Psychological Distress (PSS, 0-20, anxiety and depression). The ESAS has been validated in oncology care settings, with minimally clinically important differences constituting an important way to interpret patient reported outcome scores and determine the clinical effectiveness of an intervention. [@B10],[@B11] An individual symptom score reduction of ≥1 is considered a clinically significant change; for the ESAS subscales, reduction of GDS≥3, PHS≥ 2, and PSS≥2 indicates clinically significant changes.

Intervention
------------

Acupuncture treatment was provided in a clinical space within our outpatient center by licensed, experienced (\>10 years) staff acupuncturists credentialed through the institution\'s Medical Staff Office. During an acupuncture treatment, small, sterile, stainless steel needles, typically ranging from 32-40 gauge, were inserted into specific acupuncture points on the body and left in place for 20-30 minutes. The needle\'s effects may have been augmented with manual or electrical stimulation and/or heat. The length and frequency of acupuncture treatments varied according to the condition being treated per professional judgement of the acupuncturist. Typically, two treatments weekly for 3-4 weeks, are initially recommended, but treatment plans can vary according to the symptoms being addressed. Treatments may then decrease in frequency as the treatment plan progresses and desired results are achieved. Initial acupuncture visit duration was approximately one hour, with follow up visits lasting approximately 30-45 minutes.

Statistics
----------

Demographics, baseline ESAS individual symptoms and subscales are summarized by descriptive statistics which include frequencies and proportions for categorical and mean +/- standard deviation and median (range) for continuous variables. Change in pre/post ESAS symptoms and subscales for those who have a symptom score at baseline of 1 or greater was evaluated by paired t-test. Pre/Post acupuncture treatment ESAS data availability was reported for all patients and for those with a baseline score of at least 1. Completion rate was calculated for pre and post treatment symptoms scores. ESAS completion is defined as completing 80% or more of the questionnaire (13 out of 16 questions). The change in ESAS symptoms and subscales pre-session from baseline to first visit was evaluated by paired t-test for those patients who had their first follow-up visit within 30 days of baseline. Response was defined as any reduction in symptom score (greater or equal to 1 point). Response rate was calculated and reported along with a Clopper-Pearson (exact) confidence interval for patients who had a baseline score of greater or equal to 1 and had at least one follow-up visit within 30 days. The association of demographics and baseline ESAS symptoms with number of follow-up visits (0 vs \>=1) was evaluated by chi-square/Fisher\'s exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Next, pre-treatment symptom score change from baseline to the last treatment (i.e. pre-treatment last session - pre-treatment first session) was compared between patients who had total of 4 or 5 treatments with those who 6 or more treatments. The association of response rate and follow-up status (no follow-up vs at least 1 follow-up) was evaluated by chi-square (or Fisher\'s exact) test. The probability of \'at least one follow-up visit\' was evaluated for association with response to treatment by applying a logistic regression model. Estimates of odds ratio and its 95% confidence interval are reported.

Results
=======

We examined data for 375 unique patients receiving acupuncture treatment between January and December 2016, with a mean number of acupuncture treatments of 4.6 (range: 1-48, SD 5.1) for a total of 1728 treatments during the time period \[Table [1](#T1){ref-type="table"}\]. Pre-treatment ESAS data were available for 352/375 (93.9%) at the baseline encounter; pre- and post-treatment ESAS data were available for 253/375 (68.3%) of the initial/baseline encounters, with 275 patients (73.3%) having at least one follow up visit. The mean number of days from initial consult to first follow up was 10 (SD 20.3) days, with 259/375 (69%) having their first follow up treatment within 30 days. Patient characteristics included mean age of 55.6, mostly female (68.3%), white/caucasian (73.9%), married or with significant other (76%), and living locally (49.6%). Most common cancer types included breast, thoracic/head and neck, and gastrointestinal. The distribution of marital status and residency location is different between patients who had at least one follow-up visit and those who had no follow-ups.

Baseline symptoms at initial acupuncture treatment
--------------------------------------------------

The most frequently reported symptoms on initial presentation included sleep (81.3%), well-being (79.2%), and fatigue (77.6%). The highest self-reported symptom scores on initial presentation were: sleep 3.9 (SD 2.7), fatigue 3.4 (SD 2.6), well-being 3.3 (SD 2.3), pain 3.3 (SD 2.7), and poor memory 3 (SD 2.4) \[Table [2](#T2){ref-type="table"}\]. Moderate intensity symptom scores (4-7) were observed for symptoms of sleep (4.5), numbness tingling (4.5), hot flash (4.4), fatigue (4.2), pain (4.1) and dry mouth (4).

Immediate pre-post effects of acupuncture treatment
---------------------------------------------------

Immediate pre-post effects of acupuncture treatment were significant across all symptoms and subscales (p\<0.001). Clinically significant effects were observed for symptoms of anxiety (-1.42), appetite (-1.01), depression (-1.14), dry mouth (-1.18), fatigue (-1.72), hot flash (-1.93), nausea (-1.67), numbness/tingling (-1.70), pain (-1.57), shortness of breath (-1.55), sleep (-1.06), spiritual pain (-1.11), and well-being (-1.16). ESAS subscale scores of GDS, PHS, and PSS also showed clinically significant improvement.

Longitudinal effects of acupuncture treatment
---------------------------------------------

Of the 259 patients who had their first acupuncture follow-up visit within 30 days from the baseline, 215 (83.0%) completed pre-treatment ESAS measures at their first visit. Of this sample, pre-treatment measures at both acupuncture sessions (initial and follow-up) were available for 209 (80.7%) patients. Statistically significant improvement between the baseline (pre-initial treatment) and follow-up (pre-follow up treatment) ESAS scores was observed for all symptoms except appetite \[Table [3](#T3){ref-type="table"}\]. Both statistically and clinically significant improvement was observed for the symptom of spiritual pain (-1.10; p\<0.001). Although we observed statistically significant improvement for ESAS subscales of GDS and PSS, these remained clinically significant only for GDS. Clinical response rates were greater than 50% for symptoms of nausea, shortness of breath, well-being, spiritual pain, hot flashes, numbness/tingling, and dry mouth \[Table [3](#T3){ref-type="table"}\]. On evaluation of the association of response to the first treatment and likelihood of follow-up, there was only a statistically significant association between hot flashes and follow-up (p=0.014). The odds of having at least one follow-up is 3.3 times higher for those who did not respond to their first treatment with regards to hot flashes compared to those who did respond (data not shown).

Since most treatment plans included the recommendation for 1 to 2 acupuncture treatments per week for 4 weeks, we also analyzed overall symptom score change from pre-treatment at baseline to the pre-treatment at the last session in patients who had 4 or more treatments within a 30 days period (n=137; 38%). We compared the population of patients with a total of 4 or 5 acupuncture treatments (n=68) with those who had at least 6 treatments (n=69). Our analyses do not indicate any statistically significant association between number of treatments (4 or 5 *versus* 6 or more) and pre-treatment symptom score change from the first to the last treatment (data not shown).

Discussion
==========

Our results can serve an important role in the design of future clinical trials as well as helping to inform real-world clinical practice. A recently published National Cancer Institute monograph based on a symposium "Acupuncture for Cancer Symptom Management," identified as a future direction the need to advance the evidence-based integration of acupuncture into conventional cancer care settings.[@B12] Areas of practice improvement highlighted included exploration of acupuncture effects on symptoms clusters, performing pragmatic trials to evaluate effectiveness of acupuncture as part of usual care, and identifying patient-reported outcomes of relevance in oncology acupuncture practice.

Our goals were to learn about the effects of acupuncture on self-reported symptoms when offered in a clinical setting alongside conventional oncology care. We observed statistically and clinically significant reduction/improvement in most individual ESAS symptoms and across all subscales after a single acupuncture treatment. At first follow up, we also observed statistically significant improvement across most symptoms surveyed, with clinically significant improvement in the individual symptom of spiritual pain and global and physical distress subscales. Clinical response rates were near or above 50% for the majority of individual symptoms analyzed. We also learned about the feasibility of collecting immediate pre/post and longitudinal self-reported outcome data as part of routine clinical practice in an integrative medicine center offering acupuncture and other complementary health approaches, with pre-treatment patient reported outcome data available in greater than 90% of encounters and both pre/post treatment data available in greater than 65% of encounters.

A strength of this study is that it mimics current clinical practice for acupuncture. Acupuncture treatments were based on the best clinical judgement of acupuncturists in our clinical center, not on a standardized treatment protocol. There are several limitations, however. First, although these findings provide important information for the design of future trials, lack of a control group is a recognized limitation; thus, results should be interpreted with caution. Second, as with any study involving patient-reported symptom management, biologic measures were unavailable. Finally, the patient population is from a single integrative medicine clinic at a comprehensive cancer center, which may not be representative of the population of patients receiving acupuncture treatments in the community during their cancer care. As part of a real-world study, patients were referred to acupuncture treatments as part of the standard of care on the basis of clinical recommendation by a physician and / or advanced practice provider. Although we limited our analysis of symptom score change between initial treatment and first follow up to those treatments scheduled within 30 days, it is possible that other medical interventions (e.g., concurrent acupuncture in the community) or changes in disease course could be responsible for the changes observed.

Our findings related to clinically significant symptom score change, clinical response rates, and dose effect can help inform future studies exploring effects of acupuncture when offered in a real-life clinical setting alongside conventional cancer care. We have also learned about the feasibility of collecting patient reported outcomes as part of the standard of care in an outpatient integrative oncology program at a comprehensive cancer center. Our results suggest the potential benefit of acupuncture treatments in providing clinically significant improvements for commonly reported cancer related-symptoms during cancer care. With increased interest in the non-pharmacologic management of symptoms such as pain in the supportive care of cancer patients,[@B13],[@B14] more research is needed to better understand acupuncture mechanisms, dosing, and its effects on self-reported symptoms.

This research study was supported in part by funding from the Duncan Family Institute for Cancer Prevention and Risk Assessment.

###### 

Patient demographics and clinical characteristics at initial consult and first follow up.

                            Initial Consult (n=375)      Follow Up (n=275)   p-value^\*^        
  ------------------------- ---------------------------- ------------------- ------------------ -------------
  Age                       Mean ± Std                   55.6 ± 13.1         56.3 ± 12.4        0.18
                            Median (Min, Max)            57.0 (8.0, 88.0)    57.0 (8.0, 88.0)   
                                                                                                
  Gender                    Female                       256 (68.3%)         191 (69.5%)        0.41
                            Male                         119 (31.7%)         84 (30.5%)         
                                                                                                
  Race                      White/Caucasian              277 (73.9%)         205 (74.5%)        0.45
                            Hispanic/Latino              42 (11.2%)          32 (11.6%)         
                            Black/African American       22 (5.9%)           13 (4.7%)          
                            Asian                        20 (5.3%)           16 (5.8%)          
                            Other                        6 (1.6%)            3 (1.1%)           
                            Unknown                      8 (2.1%)            6 (2.2%)           
                                                                                                
  Marital Status            Married/Significant Other    285 (76.0%)         218 (79.3%)        **0.035**
                            Single                       46 (12.3%)          29 (10.5%)         
                            Divorced                     32 (8.5%)           18 (6.5%)          
                            Widowed                      9 (2.4%)            8 (2.9%)           
                            Unknown                      3 (0.8%)            2 (0.7%)           
                                                                                                
  Residency                 Harris County                133 (35.5%)         114 (41.5%)        **\<0.001**
                            Seven Surrounding Counties   53 (14.1%)          39 (14.2%)         
                            Rest of Texas                65 (17.3%)          40 (14.5%)         
                            Rest of US                   106 (28.3%)         71 (25.8%)         
                            International                18 (4.8%)           11 (4.0%)          
                                                                                                
  Cancer Type               Breast                       123 (32.8%)         92 (33.5%)         0.32
                            Thoracic/Head and Neck       97 (25.9%)          72 (26.2%)         
                            Gastrointestinal             57 (15.2%)          37 (13.5%)         
                            Lymphoma/Myeloma             33 (8.8%)           21 (7.6%)          
                            Genitourinary                24 (6.4%)           18 (6.5%)          
                            Gynecologic                  17 (4.5%)           14 (5.1%)          
                            Leukemia                     9 (2.4%)            7 (2.6%)           
                            No evidence of disease       6 (1.6%)            6 (2.2%)           
                            Skin                         5 (1.3%)            4 (1.5%)           
                            Other                        4 (1.1%)            4 (1.5%)           
                                                                                                
  Number of treatments      Mean ± Std                   4.61 ± 5.12                            
                            Median (Min, Max)            3.0 (1.0, 48.0)                        
                                                                                                
  Days to 1^st^ follow-up   Mean ± Std                   10.06 ± 20.34                          
                            Median (Min, Max)            5.0 (1.0, 193.0)                       

^\*^Represents comparison between those did not follow up (n=100) and those with at least one follow up (n=275). Significant difference is represented in bold.

###### 

Baseline mean symptom scores and single treatment symptom score change.

  --------------------------------------------------------------------------------------------------------------------
  ESAS Symptoms         All Patients treated\   n^\*^   Pre\            Post\           Mean change^\*\*^    p-value
                        Mean (SD)                       Mean (SD)       Mean (SD)                            
  --------------------- ----------------------- ------- --------------- --------------- -------------------- ---------
  Pain                  3.29 (2.66)             280     4.13 (2.32)     2.07 (2.16)     **-1.57 (1.69)**     \<.001

  Fatigue               3.43 (2.55)             291     4.15 (2.20)     2.13 (2.06)     **-1.72 (1.82)**     \<.001

  Nausea                0.90 (1.80)             112     2.82 (2.18)     0.40 (0.96)     **-1.67 (2.10)**     \<.001

  Shortness of Breath   0.94 (1.70)             116     2.86 (1.82)     0.50 (1.27)     **-1.55 (1.54)**     \<.001

  Appetite              2.68 (2.64)             237     3.98 (2.26)     2.07 (2.27)     **-1.01 (2.09)**     \<.001

  Drowsiness            1.85 (2.19)             210     3.10 (2.05)     1.48 (1.85)     -0.97 (1.90)         \<.001

  Depression            1.30 (1.95)             149     3.07 (1.87)     0.90 (1.55)     **-1.14 (1.40)**     \<.001

  Anxiety               2.03 (2.23)             221     3.23 (2.01)     1.14 (1.65)     **-1.42 (1.71)**     \<.001

  Sleep                 3.92 (2.68)             305     4.52 (2.36)     3.16 (2.52)     **-1.06 (2.08)**     \<.001

  Well-being            3.31 (2.30)             297     3.90 (1.99)     2.39 (2.07)     **-1.16 (1.81)**     \<.001

  Spiritual Pain        0.89 (1.69)             107     2.91 (1.86)     0.59 (1.37)     **-1.11 (1.63)**     \<.001

  Financial Distress    1.84 (2.61)             171     3.78 (2.58)     1.73 (2.53)     -0.69 (1.59)         \<.001

  Hot flashes           1.91 (2.8)              151     4.42 (2.65)     1.13 (2.11)     **-1.93 (2.26)**     \<.001

  Numbness/tinging      2.89 (2.99)             226     4.48 (2.59)     1.89 (2.34)     **-1.70 (1.90)**     \<.001

  Dry mouth             2.24 (2.69)             197     4.01 (2.41)     1.63 (2.21)     **-1.18 (1.76)**     \<.001

  Memory                3.06 (2.39)             290     3.71 (2.13)     2.51 (2.18)     -0.83 (1.57)         \<.001

  GDS^1^                19.72 (13.09)           34      34.91 (13.06)   13.01 (10.17)   **-12.18 (10.28)**   \<.001

  PHS^1^                13.09 (8.9)             45      22.82 (8.66)    8.57 (6.76)     **-8.46 (6.42)**     \<.001

  PSS^1^                3.34 (3.75)             136     6.73 (3.50)     2.03 (2.91)     **-2.57 (2.89)**     \<.001
  --------------------------------------------------------------------------------------------------------------------

\* Patients with individual symptom score of at least 1 on the pre-treatment ESAS. For ESAS subscale calculation, all symptoms in subscale must have score of at least 1 to be included.

\*\* For all symptoms, a change score of ≥1 is considered clinically significant. For predetermined subscales, clinical significance is defined as follows: ≥3 for GDS; ≥2 for PHS and PSS. Clinically significant change in bold.

[@B1] GDS (Global distress score) equals sum of pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath (total score 0-90); PHS (physical distress score) equals sum of pain, fatigue, nausea, drowsiness, appetite, and shortness of breath (total 0-60); and PSS (psychological distress score) equals sum of depression and anxiety.

###### 

Symptom score change between first treatment and first follow up.

  --------------------------------------------------------------------------------------------------------------------------------
  ESAS Symptoms         n^\*^   Initial\        Follow Up\      Mean change^\*\*^   p-value   n^┼^   Clinical response rates^┼┼^
                                Mean (SD)       Mean (SD)                                            
  --------------------- ------- --------------- --------------- ------------------- --------- ------ -----------------------------
  Pain                  205     4.07 (2.33)     2.98 (2.41)     -0.53 (2.17)        \<.001    197    47.2% (39.9%, 54.5%)

  Fatigue               216     4.10 (2.14)     3.11 (2.49)     -0.50 (2.26)        0.004     205    44.5% (37.5%, 51.7%)

  Nausea                78      2.55 (1.93)     0.84 (1.67)     -0.56 (1.87)        0.011     76     57.3% (45.4%, 68.7%)

  Shortness of Breath   79      2.85 (1.80)     0.77 (1.52)     -0.78 (2.00)        0.001     75     50.7% (38.7%, 62.6%)

  Appetite              169     4.04 (2.23)     2.63 (2.65)     -0.34 (2.68)        0.112     162    48.4% (40.4%%, 56.5%)

  Drowsiness            151     2.98 (1.95)     1.72 (1.99)     -0.44 (1.93)        0.007     147    48.2% (38.8%, 55.7%)

  Depression            108     2.94 (1.79)     1.19 (1.84)     -0.51 (1.72)        0.003     104    40.6% (30.9%, 50.8%)

  Anxiety               162     3.08 (1.91)     1.76 (2.08)     -0.53 (1.96)        0.001     151    48.6% (40.3%, 57.0%)

  Sleep                 225     4.47 (2.33)     3.56 (2.49)     -0.57 (2.27)        \<.001    213    46.8% (39.8%, 53.9%)

  Well-being            217     3.95 (1.96)     3.04 (2.37)     -0.57 (1.86)        \<.001    205    53.0% (45.8%, 60.1%)

  Spiritual Pain        78      2.97 (1.85)     0.69 (1.53)     **-1.10 (2.13)**    \<.001    75     58.9% (46.8%, 70.3%)

  Financial Distress    122     3.63 (2.48)     1.52 (2.39)     -0.54 (1.17)        0.007     116    49.1% (39.5%, 58.7%)

  Hot flashes           103     4.39 (2.68)     1.74 (2.64)     -0.78 (2.15)        \<.001    97     55.9% (45.2%, 66.2%)

  Numbness / tinging    165     4.55 (3.02)     2.57 (2.79)     -0.75 (2.02)        \<.001    154    52.4% (44.0%, 60.6%)

  Dry mouth             150     4.22 (2.43)     2.08 (2.50)     -0.73 (2.02)        \<.001    140    57.8% (49.0%, 66.2%)

  Memory                209     3.61 (2.10)     2.63 (2.31)     -0.43 (1.63)        \<.001    196    47.6% (40.4%, 55.0%)

  GDS^1^                24      34.54 (12.80)   18.04 (12.70)   **-6.09 (13.96)**   0.048     24     47.8% (26.8%, 69.4%)

  PHS^1^                32      22.48 (8.77)    12.05 (8.51)    **-3.23 (9.37)**    0.069     31     50.0% (31.3%, 68.7%)

  PSS^1^                95      6.41 (3.26)     2.96 (3.61)     -0.84 (3.40)        0.023     91     33.0% (23.3%, 43.8%)
  --------------------------------------------------------------------------------------------------------------------------------

^\*^ Patients with at least one follow up treatment and with an individual symptom score of at least 1 on the pre-treatment ESAS. For ESAS subscale calculation, all symptoms in subscale must have score of at least 1 to be included.

^\*\*^ For all individual symptoms, a change score of ≥1 is considered clinically significant. For predetermined subscales, clinical significance is defined as follows: ≥3 for GDS; ≥2 for PHS and PSS. Clinically significant change in bold.

^┼^ Patients with first follow up treatment within 30 days and with an individual symptom score of at least 1 on the initial visit, pre-treatment ESAS. All symptoms in subscale must have score of at least 1 to be included in the response rate analysis.

^┼┼^ Clinical response rate (95% confidence interval) defined as a 1-point decrease or more in score on the ESAS individual symptoms; 2-point decrease or more in score on the ESAS PSS; 3-point decrease or more in score on the ESAS PHS and GDS.

[@B1] GDS (Global distress score) equals sum of pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath (total score 0-90); PHS (physical distress score) equals sum of pain, fatigue, nausea, drowsiness, appetite, and shortness of breath (total 0-60); and PSS (psychological distress score) equals sum of depression and anxiety.
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